The global oncologic disorders testing industry is exhibiting significant expansion, propelled by a rising prevalence of myeloma and other related illnesses. Researchers estimate the present market value to be substantial, with projections indicating a steady compound annual increase rate (CAGR) over the projected period. Key drivers shaping the la